Avricore Health Closes $1.254 Million Financing

Executive Summary

• Avricore Health Inc. closed a non-brokered private placement on June 16, 2026, raising $1,254,000 in gross proceeds to fund general working capital and support its UK expansion strategy.
• The company issued 25,080,000 units at $0.05 per unit, with each unit comprising one common share and one-half transferrable share purchase warrant.
• Insiders participated in the offering with $200,000 in investments, and the transaction includes specific finder's fees and warrant terms for Canaccord Genuity Corp.

Key Details

• Gross Proceeds: $1,254,000
• Units Issued: 25,080,000 at $0.05 per unit
• Closing Date: June 16, 2026
• Unit Composition: Each unit consists of one common share and one-half transferrable share purchase warrant
• Warrant Terms: Each warrant entitles the holder to purchase one additional common share at $0.10 per share for a period of 2 years from the closing date
• Use of Proceeds: General working capital purposes and UK expansion
• Finder's Fees: $54,600 paid to Canaccord Genuity Corp. (an arm’s length finder)
• Finders Warrants: 1,092,000 non-transferable warrants issued to Canaccord Genuity Corp., exercisable at $0.05 per share for 2 years from closing
• Insider Participation: Insiders invested an aggregate of $200,000 for 4,000,000 units; directors and officers participated, constituting a related party transaction
• Regulatory & Compliance: Closing is subject to final acceptance by the TSX Venture Exchange; all securities carry a four-month hold period under Canadian securities laws; the related party transaction is exempt from MI 61-101 minority approval, information circular, and formal valuation requirements as insider consideration does not exceed 25% of market capitalization
• Filing Schedule: A material change report will be filed less than 21 days before the closing date

Notable Quotes

• Rodger Seccombe, CEO: "This financing provides the Company with the capital strength for its UK expansion. We appreciate the commitment from our investors as we prepare to execute on our growth strategy."